An interventional study of 419 nm Spectacle Filter and 437 nm Spectacle Filter in Photosensitivity, sponsored by Johnson & Johnson Vision Care, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-25.
Sponsored by Johnson & Johnson Vision Care, Inc. (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment
Among 12 studies in Photosensitivity Disorders with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Photosensitivity Disorders · United States.
Among the 12 studies in Photosensitivity Disorders with a site in United States, this one is the only one that started in 2021, is one of 3 with no phase, and was the 10th registered.
25 studies on the registry are indexed under Photosensitivity Disorders; 4 are open to participants now.
This study's enrollment of 53 is above the median of 38 across 18 interventional studies indexed under Photosensitivity Disorders.
Browse Photosensitivity Disorders studies →2 of the 12 studies in Photosensitivity Disorders with a site in United States are open now, in 1 country. Each count lists the studies.
Of the 4 Photosensitivity Disorders studies recruiting now, 2 (50%) set no upper age limit and 2 (50%) stop at 75 or younger; 0 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 30 Years · all sexes · healthy volunteers too.
The full table on the hub →12 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2021.
Median enrollment 24 across the 9 interventional studies, 537 across the 3 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
3 of 12 have an industry lead sponsor. The 10 most frequent:
Johnson & Johnson Vision Care, Inc. is the lead sponsor of 221 studies on the registry; 1 is open to participants now.
Of its 111 completed or terminated interventional studies of FDA-regulated products, 103 (93%) have results posted.
Johnson & Johnson Vision Care, Inc. has 1 study filed under Photosensitivity Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies in Photosensitivity Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520217Wright State UniversityTesting Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects | 2026-12-01 |
Among the 12 studies in Photosensitivity Disorders with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This is a 6-visit, single-center, non-dispensing, randomized, single-masked, 5×5 crossover study. Subjects will participate in 6 scheduled over the duration of approximately 10.5 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(419nm, 437nm, 373nm, 456nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 1.
Other: 419 nm Spectacle Filter · Other: 437 nm Spectacle Filter · Other: 456 nm Spectacle Filter · Other: 476 nm Spectacle Filter · Other: 373 nm Spectacle Filter
(437nm, 456nm, 419nm, 476nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 2.
Other: 419 nm Spectacle Filter · Other: 437 nm Spectacle Filter · Other: 456 nm Spectacle Filter · Other: 476 nm Spectacle Filter · Other: 373 nm Spectacle Filter
(456nm, 476nm, 437nm, 373nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 3.
Other: 419 nm Spectacle Filter · Other: 437 nm Spectacle Filter · Other: 456 nm Spectacle Filter · Other: 476 nm Spectacle Filter · Other: 373 nm Spectacle Filter
(476nm, 373nm, 456nm, 419nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 4.
Other: 419 nm Spectacle Filter · Other: 437 nm Spectacle Filter · Other: 456 nm Spectacle Filter · Other: 476 nm Spectacle Filter · Other: 373 nm Spectacle Filter
(373nm, 419nm, 476nm, 437nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 5.
Other: 419 nm Spectacle Filter · Other: 437 nm Spectacle Filter · Other: 456 nm Spectacle Filter · Other: 476 nm Spectacle Filter · Other: 373 nm Spectacle Filter
(476nm, 456nm, 373nm, 437nm, 419nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 6.
Other: 419 nm Spectacle Filter · Other: 437 nm Spectacle Filter · Other: 456 nm Spectacle Filter · Other: 476 nm Spectacle Filter · Other: 373 nm Spectacle Filter
(373nm, 476nm, 419nm, 456nm, 437nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 7.
Other: 419 nm Spectacle Filter · Other: 437 nm Spectacle Filter · Other: 456 nm Spectacle Filter · Other: 476 nm Spectacle Filter · Other: 373 nm Spectacle Filter
(419nm, 373nm, 437nm, 476nm, 456nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 8.
Other: 419 nm Spectacle Filter · Other: 437 nm Spectacle Filter · Other: 456 nm Spectacle Filter · Other: 476 nm Spectacle Filter · Other: 373 nm Spectacle Filter
(437nm, 419nm, 456nm, 373nm, 476nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 9.
Other: 419 nm Spectacle Filter · Other: 437 nm Spectacle Filter · Other: 456 nm Spectacle Filter · Other: 476 nm Spectacle Filter · Other: 373 nm Spectacle Filter
(456nm, 437nm, 476nm, 419nm, 373nm) Eligible subjects will be enrolled in Spectacle Filter Sequence 10.
Other: 419 nm Spectacle Filter · Other: 437 nm Spectacle Filter · Other: 456 nm Spectacle Filter · Other: 476 nm Spectacle Filter · Other: 373 nm Spectacle Filter
TEST
TEST
TEST
TEST
CONTROL
Visual Photosensitivity Threshold (VPT)
VPT will measured via the SAOPA instrument. VPT is the point at which a sensation of pain or discomfort occurs when the intensity of light is gradually increased from a low level. Subject's discomfort responses will be indicated via a button press. Testing is complete when 10 response reversals are acquired.
Time frame: at approximately 2-week follow-up
Plan to share: Yes — Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu
Data sharing details ↗ · yoda.yale.edu
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in May 2022, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johnson & Johnson Vision Care, Inc. →